CA
NZ
UK
AU
IND
US
Global oil markets are confronting one of their most acuteSupplyshocks in recent memory. On Wednesday,Brent Crudefutures surged more than 5% to trade above USD 117 per barrel, a level not seen since June 2022. The move reflects mounting anxiety over a conflict involving Iran …
The latest weekly data from the US Energy Information Administration marks more than a routine inventory report. For the first time in recorded weekly data going back to 2001, the United States registered negative net crude imports, with exports of 6.44 million barrels per …
A Rare Respiratory Disease Company Reaches the Public Stage
Celestica Inc. operates within a dynamic segment of the technologySupply/">Supplychain, benefiting from structural tailwinds such as AI-driven infrastructure expansion,Cloud ComputingDemand/">Demand, and industrial automation. Given the stock’s sensitivity toEarnings/">Earningsmomentum,Margin/">Marginexpansion, and macro-driven capex cycles, price movements can be sharp and directional. For traders expecting near-term strength …
Shares of Quantum BioPharma Ltd. (Nasdaq:QNTM) closed at $5.37 in the lastTrading session, advancing 20.67%, after its licensee Unbuzzd Wellness Inc. announced the appointment of Richard Buzbuzian as Chief Executive Officer. The move signals a structural shift from product development toward active commercial deployment, …
Clinical Trialsin rare oncology are rarely forgiving the second time. Soligenix (Nasdaq:SNGX) learned that on April 28, 2026, when its Data Monitoring Committee terminated the Phase 3 FLASH2 study of HyBryte for cutaneous T-cell lymphoma, recommending a halt for futility at the interim efficacy …
AxoGen (Nasdaq:AXGN) closed on April 28 up 6.60%, ending at USD 41.99, as first-quarter 2026 results cleared expectations on theRevenueline by a meaningfulMargin.Revenueof USD 61.5 million surpassed analyst forecasts of USD 57.85 million by 6.24%, driven by broad-basedDemandfor Avance Nerve Graft across the company's …
Glioblastoma remains among the most treatment-resistant cancers known to medicine. Median survival after diagnosis hovers around 15 months, and the therapeutic landscape has seen little meaningful innovation in over two decades. Against this backdrop, BioLineRx (Nasdaq:BLRX) and its partner Hemispherian AS announced on April …
In clinical-stage biotechnology, a single adverse event can reset years of accumulated investor confidence within hours. For Erasca (Nasdaq: ERAS), two successive sessions delivered compounding shocks: aPatentdispute on April 27 and a treatment-linked fatality disclosed on April 28, sending shares down 48.30% to close …
NeuroSense Therapeutics (Nasdaq:NRSN) surged 7.78% after announcing a USD 600,000 insider-led PIPE financing, with the CEO and CFO each committing USD 200,000 at a premium toMarket Priceahead of key clinical and regulatory milestones.Key HighlightsNeuroSense Therapeutics closed up 7.78% at USD 0.81 on April 28, …
Please wait processing your request...